Add-on prolonged-release melatonin for cognitive function and sleep in mild to moderate Alzheimer's disease: a 6-month, randomized, placebo-controlled, multicenter trial.

Clin Interv Aging · 2014 · PMC4069047 · PMID 24971004

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Effects on sleep Most patients in the FAS population did not have insomnia, and thus, as expected, the treatment effect of PRM compared with that of placebo on the global PSQI score did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.